Skip to content

    Syngene International Limited

    SYNGENEGood
    Healthcare·24 Jul 2025
    Management Summary

    Syngene delivered a positive start to FY26, characterized by strong momentum in Research Services and significant margin expansion. The company successfully operationalized its Unit 3 biologics facility and inaugurated a new peptide laboratory to capture high-growth modalities like GLP-1s. Despite continued uncertainty in global biotech funding, management remains confident in its full-year outlook, supported by a healthy pipeline from large and mid-sized pharma companies.

    Highlights

    7

    • Reported revenue from operations reached ₹875 crores, an 11% YoY increase (7% in constant currency).

    • Operating EBITDA grew 21% YoY to ₹206 crores, with margins expanding 200bps to 24%.

    • Profit After Tax (before exceptional items) rose 59% YoY to ₹87 crores, aided by a one-time tax adjustment.

    • Research Services performed strongly, accounting for 67% of total sales during the quarter.

    • Unit 3 biologics facility in Bengaluru became operational and delivered its first GMP clinical batch.

    • Raw material costs improved significantly to 25% of revenue compared to 30% in the previous year.

    • Management reiterated full-year guidance of mid-single digit reported revenue growth and early teens underlying growth.

    Concerns

    1

    • Biotech Funding Uncertainty

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue from Operations₹875 Cr+11%YoY
    2. 02Operating EBITDA₹206 Cr+21%YoY
    3. 03EBITDA Margin24%
    4. 04PAT (before exceptional)₹87 Cr+59%YoY
    5. 05Net Cash₹1,053 Cr

    Segment breakdown

    Research Services
    67% Revenue Mix
    CDMO
    33% Revenue Mix
    List

    Guidance & targets

    6
    CategoryTargetPriority
    Revenue
    Reported Revenue Growth
    mid-single digits
    		High
    Revenue
    Underlying Revenue Growth
    early teens
    		High
    Margin
    EBITDA Margin
    mid-20s
    		Medium
    Other
    Raw Material Cost as % of Revenue
    26%
    		High
    Other
    Effective Tax Rate
    24%
    		High
    Capacity
    Bayview Biologics Operationalization
    Operational
    		High

    Risks & concerns

    5
    RiskSeverity

    Biotech Funding Uncertainty

    Biotech funding has not yet stabilized or returned to pre-pandemic levels, impacting early-stage discovery demand. — Management acknowledged

    high

    Inventory Rebalancing in Biologics

    Expected inventory adjustments in commercial manufacturing will weigh on reported revenue growth for the full year. — Management acknowledged

    medium

    Senior Level Attrition

    Analyst raised concerns over historical senior attrition; management countered that the company remains stable with long-tenured leaders. — Analyst downplayed

    medium

    Areas of Evasion(2)

    • Specific quantitative utilization numbers for Mangalore and Unit 3 facilities.
    • Exact timelines for dedicated center contract renewals.

    Q&A highlights

    3

    “We're 12 weeks into the year, and I think it's just too early for us to make adjustments at this stage... We want to see more visibility through the year.”

    Management is being cautious despite an 11% growth start, citing upcoming inventory adjustments in the Biologics segment.

    asked by Kunal Dhamesha, Macquarie

    2 min read5 chapters

    Detailed Narrative

    01

    Research Services Leads Growth Momentum

    Research Services was the standout performer in Q1, contributing 67% of total revenue. This growth was driven by the successful transition of pilot programs into longer-term contracts and increased demand from large and mid-sized pharma. Management highlighted that despite the biotech funding crunch, the segment's 11% growth demonstrates resilience and a diversified client base.

    02

    Operational Milestones in Biologics and Peptides

    A major milestone was achieved with Unit 3 in Bengaluru becoming operational and delivering its first GMP clinical batch for a US client. Additionally, the company inaugurated a state-of-the-art peptide laboratory to target the rapidly emerging GLP-1 class for diabetes and obesity. These investments are expected to drive medium-term growth as utilization ramps up over a 3-to-5-year horizon.

    03

    Margin Expansion Through Cost Efficiency

    Operating EBITDA margins expanded to 24% from 22% YoY, primarily due to a favorable business mix and improved raw material yields. Raw material costs dropped to 25% of revenue this quarter, though management expects this to normalize to 26% for the full year. Automation in DMPK operations has already reduced turnaround times from 5 days to 3 days, enhancing cost efficiency by 30%.

    04

    Strategic Expansion in the US Market

    Syngene is making steady progress at its Bayview Biologics facility in the US, with revalidation and integration efforts on track for operationalization in H2 FY26. The facility's versatility, featuring three discrete suites, has already garnered healthy interest from potential customers. This site provides a critical local footprint to mitigate geopolitical risks and capture US-based demand.

    05

    Leadership Strengthening and Sustainability Focus

    The company bolstered its leadership team with three key appointments: Dr. Priyaranjan Pattanaik (Discovery Biology), Gaurav Kushwaha (CTO), and Ajay Tandon (Head of Corporate Development). These hires are aimed at driving AI-led digital transformation and strategic growth. Furthermore, Syngene was recognized by Time Magazine as the most sustainable pharma/biotech company in India.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.